To advance the understanding and treatment of liver disease by pursuing innovative, transformative basic and translational ...

Industry Giants Gilead Sciences, Bristol Myers Squibb, AbbVie, and Merck & Co. Lead the CompetitionDublin, May 06, 2025 (GLOBE NEWSWIRE) -- The "Liver Disease Treatments Market" report has been added ...

The risk of dying from the most common form of primary liver cancer is about 30% higher for patients with low household ...

Among patients with hepatocellular carcinoma, MAFLD was not an independent predictor for overall survival or progression-free ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

Alcohol consumption poses a significant global health risk, contributing to numerous diseases and injuries, especially among ...

Strategic insight into the Liver Cancer Treatment Market reveals a high-growth opportunity, especially in Asia-Pacific, driven by a rising patient po ...

ACG released new guidance for the management of malnutrition in patients with liver disease, including the newly renamed ...

The Italian study showed that patients with HCC resulting from viral infections or fatty liver had significantly higher ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

MASLD is a condition where excess fat accumulates in the liver of individuals who consume little to no alcohol.

Hepatocellular carcinoma (HCC) is a common malignant tumor and the third leading cause of cancer-related mortality. The lack ...